KB Home Beats Q2 Sales
KB Home reports Q2 revenue of $1.11 billion, beating analyst estimates, and earnings of 43 cents per share, missing estimates
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results.
Select Premarket Movers
Upside: -ABSI +25% (reports positive interim Phase 1 data for ABS-201 in androgenetic alopecia; prices 13.5M share common stock offering at $7.41/shr) -WEN +22% (meme trading momentum) -RUN +20% (agrees with Renew Home, Tesla to deliver more than 16 GW flexible energy capacity to hyperscalers, utilities) -FCEL +17% (an
ABSI: Reports Interim Phase 1 Data
Absci reports interim phase 1 data from its trial of ABS-201, an investigational anti-prolactin receptor antibody, showing favorable safety data.
ABSI Reports Positive Phase 1 Data
Absci announces positive interim phase 1 data from the HEADLINE trial of ABS-201, a novel antibody targeting the prolactin receptor